Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 6/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 6/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 6/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.45 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7586649 | 0.88 | OPRM1 (0.47) | OPRM1NPFFR1NPFFR2OPRD1 | |
| SCHEMBL30561151 | 0.88 | OPRM1 (0.47) | OPRM1NPFFR1NPFFR2OPRD1 | |
| SCHEMBL497331 | 0.86 | FKBP4 (0.43) | OPRM1NPFFR1NPFFR2OPRD1 | |
| SCHEMBL29442961 | 0.86 | OPRM1 (0.45) | OPRM1NPFFR1NPFFR2OPRD1 | |
| Hydrochloric Acid SCHEMBL29793967 | 0.85 | OPRM1 (0.45) | OPRM1NPFFR1NPFFR2OPRD1 | |
| SCHEMBL30038002 | 0.83 | NPY4R (0.59) | OPRM1NPFFR1NPFFR2OPRD1 | |
| SCHEMBL8502170 | 0.83 | OPRM1 (0.42) | OPRM1 | |
| SCHEMBL32664435 | 0.82 | NTSR2 (0.58) | NTSR2NTSR1SORT1OPRM1NPFFR1 | |
| SCHEMBL5704652 | 0.82 | FKBP4 (0.48) | OPRM1NPFFR1NPFFR2OPRD1 | |
| SCHEMBL5835132 | 0.82 | FKBP4 (0.41) | NTSR2NTSR1SORT1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740954-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES | AZITRA, INC. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3638369-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES | AZITRA INC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12606610-B2 | Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes | AZITRA INC (US) | 2026-04-21 | — | — | US | disclosed |
| CN-114805365-B | Factor XIA new macrocycles carrying non-aromatic P2' groups | 百时美施贵宝公司 | 2024-07-23 | — | — | CN | disclosed |
| US-20240218049-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES | AZITRA INC (US) | 2024-07-04 | — | — | US | disclosed |
| CN-116987080-A | Macrocyclic compounds with heterocyclic P2' groups as factor XIA inhibitors | 百时美施贵宝公司 | 2023-11-03 | — | — | CN | disclosed |
| US-11773154-B2 | Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes | AZITRA INC (US) | 2023-10-03 | — | — | US | disclosed |
| CN-110845498-B | Macrocyclic compounds having heterocyclic P2' groups as factor XIA inhibitors | 百时美施贵宝公司 | 2023-02-17 | — | — | CN | disclosed |
| WO-2022272132-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL INFECTION | AZITRA INC (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-3868753-B1 | FACTOR XIA MACROCYCLIC INHIBITORS BEARING A NON-AROMATIC P2' GROUP | BRISTOL MYERS SQUIBB CO (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-114874222-A | Carrying non-aromatic P2 , Novel macrocyclic form of factor XIA | 百时美施贵宝公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114805365-A | Carrying non-aromatic P2 , Novel macrocyclic form of factor XIA | 百时美施贵宝公司 | 2022-07-29 | — | — | CN | disclosed |
| EP-3988549-A1 | MACROCYCLES WITH HETEROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-1398326-B1 | Monoclonal antibodies against recombinant stratum corneum chymotryptic enzyme (SCCE) | THORBJOERN EGELRUD (SE) | 2006-01-11 | — | — | EP | disclosed |
| EP-1398326-A2 | Monoclonal antibodies against recombinant stratum corneum chymotryptic enzyme (SCCE) | Egelrud, Torbjörn (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-0703985-B1 | RECOMBINANT STRATUM CORNEUM CHYMOTRYPTIC ENZYME (SCCE) | EGELRUD TORBJOERN (SE) | 2003-10-29 | — | — | EP | disclosed |
| US-5981256-A | NUCLEOTIDE SEQUENCE CODING A PROTEOLYTIC POLYPEPTIDE FOR THE TREATMENT OR PROPHYLAXIS OF DISEASES SUCH AS ACNE, PSORIASIS, ECZEMAS, SKIN DISORDERS, AUTOIMMUNE AND INFLAMMATORY SKIN DISEASES | ASTRA AKTIEBOLAG (SE) | 1999-11-09 | — | — | US | disclosed |
| US-5834290-A | SKIN DISORDERS SUCH AS ACNE, XERODERMA, HYPERKERATOTIC CONDITIONS, CALLOSITIES AND KERATOSIS PILARIS; ICHTHYOSES, PSORIASIS AND ECZEMAS; AUTOIMMUNE PEMPHIGUS, ACATHOLYTIC DISEASES, FAMILIAR PEMPHIGUS AND DARIER'S DISEASE | ASTRA AKTIEBOLAG (SE) | 1998-11-10 | — | — | US | disclosed |
| EP-0703985-A1 | RECOMBINANT STRATUM CORNEUM CHYMOTRYPTIC ENZYME (SCCE) | Astra Aktiebolag (SE) | 1996-04-03 | — | — | EP | disclosed |
| WO-1995000651-A1 | RECOMBINANT STRATUM CORNEUM CHYMOTRYPTIC ENZYME (SCCE) | ASTRA AKTIEBOLAG (SE) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606610-B2 | Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes | CUTA, TMPRSS11D, KLK5 | NTSR2 3395/4885NTSR1 2950/4885SORT1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.